Palumbo Wealth Management
NKTR icon

Palumbo Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Palumbo Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$628K Buy
10,369
+50
+0.5% +$3.51K 0.13% 110
2026
Q2 		$720K Buy
10,319
+146
+1% +$10.7K 0.15% 104
2026
Q1 		$732K Sell
10,173
-4,541
-31% -$259K 0.18% 89
2025
Q4 		$622K Sell
14,714
-11,440
-44% -$640K 0.15% 107
2025
Q3 		$1.49M Buy
26,154
+2,382
+10% +$78.8K 0.48% 44
2025
Q2 		$614K Buy
+23,772
New +$267K 0.19% 86

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Palumbo Wealth Management's NKTR Position: Q3 2026 in Review

Palumbo Wealth Management increased its Nektar Therapeutics (NKTR) stake by 0.48% in Q3 2026, buying an estimated $3.51K and bringing the position to 10,369 shares worth $628K. The position accounts for 0.13% of the portfolio, ranked #110.

Palumbo Wealth Management first reported a position in NKTR in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.49M in Q3 2025. 168 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Palumbo Wealth Management held 10,369 shares of Nektar Therapeutics worth $628K as of Q3 2026.
  • Palumbo Wealth Management bought 50 Nektar Therapeutics shares in Q3 2026, an estimated $3.51K.
  • Nektar Therapeutics made up 0.13% of Palumbo Wealth Management's portfolio in Q3 2026, its #110 holding.
  • Palumbo Wealth Management first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Palumbo Wealth Management's Nektar Therapeutics position peaked at $1.49M in Q3 2025.
  • 168 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Palumbo Wealth Management's 13F filing for Q3 2026, filed 13 Nov 2026.